Frequency's FX-322 well tolerated in Phase I hearing loss study

Frequency Therapeutics Inc. (Woburn, Mass.) reported preliminary data from nine patients with severe to profound sensorineural hearing loss in a Phase I trial showing that intratympanic FX-322 within 24 hours prior to receiving a cochlear implant was well tolerated with no treatment-related adverse events reported.

The single-blind, placebo-controlled, Australian trial is to enroll about 12 patients. The primary endpoint is safety, and the secondary endpoint is pharmacokinetics...